China Sees No Variant Impact On Vaccines, Builds New mRNA Plant
Million Already Inoculated Despite No Final Data
Chinese officials do not expect the new strain of coronavirus emerging in the UK to impact the efficacy of inactivated virus vaccines on the cusp of conditional approval. Meanwhile, a new plant is under construction in China for domestically developed mRNA vaccines.
You may also be interested in...
CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as Beijing shipping millions of doses around the world.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.